Pfizer
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027
Financial savings, Pfizer, Financial cost, Pfizer
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks
Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout
Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer
Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology
Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment
Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges
Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges
Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer
Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market
Pfizer Prepared to Shift Manufacturing to US in Response to Potential Trump Tariffs
Pfizer, Albert Bourla, US manufacturing, Trump tariffs, pharmaceutical industry, reshoring